The BioPharm Brief: Trials Expand Cancer, Eye Disease and Obesity Care

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and regulatory strategy. Today’s update covers a new immunotherapy option for colon cancer, progress in treating chronic thyroid eye disease, and emerging data for an investigational obesity treatment.

FDA has approved atezolizumab, marketed as Tecentriq, combined with chemotherapy as an adjuvant treatment for stage 3 colon cancer with deficient mismatch repair, or dMMR. The approval also covers Tecentriq Hybreza, the subcutaneous formulation. In the phase 3 ATOMIC trial, adding atezolizumab to chemotherapy improved 3-year disease-free survival to 86%, compared with 76% for chemotherapy alone. The findings offer a new treatment option for patients at risk of cancer recurrence, although grade 3 or 4 adverse events were more frequent with the combination.

Beyond oncology, researchers are also pursuing treatment options for patients with chronic thyroid eye disease, particularly those whose symptoms persist after the active inflammatory phase. Innovent Biologics reported that its phase 3 RESTORE-3 trial met its primary endpoint for Sycume, or teprotumumab N01, in patients with inactive thyroid eye disease in China. At week 24, 60.4% of patients receiving the antibody achieved a proptosis response, compared with 23.5% receiving placebo. The results suggest the insulin-like growth factor 1 receptor-targeting therapy may help address persistent eye bulging, which has often required surgery. Full trial data and longer-term follow-up remain important next steps.

Meanwhile, the obesity drug pipeline continues to expand beyond established incretin-based therapies. Zealand Pharma reported that its investigational amylin analog petrelintide met the primary endpoint in the phase 2b ZUPREME-2 trial in adults with overweight or obesity and type 2 diabetes. At 28 weeks, participants lost up to 9.2% of their body weight, compared with 2.0% with placebo. Petrelintide also improved blood glucose control, with no unexpected safety signals reported. Zealand and Roche have begun a phase 3 program to evaluate the drug in larger populations.

Across these developments, clinical trials and regulatory decisions are expanding treatment possibilities while highlighting the need to assess durability, safety, and benefit across different patient populations.

Thanks for listening to The BioPharm Brief. For further analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

• FDA approval of atezolizumab plus chemotherapy introduces an adjuvant immunotherapy option for stage 3 dMMR colon cancer.
• Innovent reports positive phase 3 results for Sycume in inactive thyroid eye disease.
• Petrelintide shows weight-loss and glycemic benefits in phase 2b testing, advancing toward phase 3 evaluation.